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This paper addresses the diagnosis and management of superior vena cava syndrome
(SVCS) due to malignant intrathoracic tumours. Diagnosis ofSVCS is usually established
by bedside examination. Chest X-ray and computed tomography may be helpful, but the
cavography remains the "gold-standard. Other imaging techniques (MRI, nuclear flow
studies) are more of scientific interest. Bronchoscopy helps to evaluate the risk of pulmo-
nary complications and endoscopic procedures often lead to histological findings. In the
treatment of malignant SVCS surgery, radiotherapy, and chemotherapy have been success-
fully used. The placement of a vascular stent might be an additional or alternative possi-
bility. There are no conclusive indication criteria and no conclusive regimen concerning
post-stenting anticoagulation. From all reported results and published papers we draw the
conclusion that the immediate effects of stent implantation and the long-term results of
tumour-specific therapy are complementary to one another. The stent dilates the local
venous stenosis while tumour-specific therapy has a general effect on the vascular and
respiratory situation in a multi-therapy concept.
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SYMPTOMS AND CAUSES OF SUPERIOR
VENA CAVA SYNDROME
The superior vena cava (SVC) is the the major
drainage system for blood from the upper part of
the body including the head and the arms. It is a
thin walled vessel measuring ca. 6cm in length and
1.5-2.0cm in width, and is formed by the union of
both brachiocephalic veins and leading towards
the right atrium. The azygos vein is the only vein
that enters the SVC, it carries blood from the
thoracic wall and the thoracic organs.
The superior vena cava syndrome (SVCS) is
characterized by venous congestion of the upper
extremities, head, and neck in most of the patients
[1] (Fig. 1). While these symptoms often appear
slowly and are not noticed by the patient severe
dyspnoea often makes the patient look for medical
advice. The dyspnoea is usually aggravated by
bending forward and in supine position [1], which
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FIGURE Swelling of head and neck due to severe venous congestion in a patient with SVCS due to bronchial carcinoma.
makes the patient looking for an upright position
at night. Oedema of the glottis is a life-threatening
effect of the venous congestion [2]. Collateral veins
at the thoracic wall are visible in the majority of
cases if the condition has existed for any length of
time [3]. Cyanosis is present in 13-20% of the
patients [1,4], neurological symptoms like head-
ache, alteration in the state of consciousness, and
visual disturbance are found in varying frequencies
[1,5-8].
Causes: In 85-97% SVCS occurs due to ma-
lignant intrathoracic tumors [9]. In a large review
of 125 cases by Armstrong et al. pulmonary
tumours were responsible for 80% of the SVCS,
further 14% were due to thoracic lymphomas [4].
Other tumours like leiomyosarcoma of thoracic
vessels or plasmocytoma have been reported to
cause SVCS in single cases [10,11]. On the other
hand in 5-15% of cases with intra-thoracic ma-
lignant tumours SVCS developes [12,13].
Benign causes include tuberculous mediastinitis,
syphilitic aortic aneurysms, mediastinal fibrosis,
post-irradiation fibrosis, posttraumatic strictures,
and intrathoracic goiter [14-18]. Iatrogenic causes
for SVCS like catheter manipulations, pacemaker
wire implantation, and aortic valve replacement
must also be taken into consideration [19-21].
This article addresses the influence of intra-
thoracic tumours on the vena cava superior and
the tracheobronchial system. We want to give anSUPERIOR VENA CAVA SYNDROME 85
overview about the clinical value of vascular and
bronchological diagnostics and therapeutics in
SVCS due to intrathoracic tumours.
VASCULAR, IMAGING AND
BRONCHOLOGICAL DIAGNOSTICS
Diagnosis of the SVCS is established by bedside
examination of the patient in a high percentage
of patients. Further diagnostic procedures in-
clude chest X-ray, computed tomography (CT),
venography, radionuclide studies, Doppler flow
studies, magnetic resonance imaging (MRI),
and bronchoscopy.
Chest X-ray proves useful in 67-78% showing
a superior mediastinal enlargement, a right hilar
mass, and the intra-thoracic tumour [1,4]. These
changings are not specific and require further in-
vestigations. CT provides more accurate informa-
tion on localization of the obstruction and size of
the tumour [14]. It also shows whether the SVC
is totally or partially surrounded by tumour or
whether the vessel is tangential to the tumour.
These details may predict the outcome after stent
implantation [22]. The venography (Fig. 2) is an in-
vasive procedure and is usually performed simul-
taneously via both cubital veins [1,5,18,23,24]. Its
disadvantages are the use of iodinated contrast
media with the inherent risk of anaphylactic reac-
tion and the increased risk of thrombus formation
[14]. Nevertheless, the cavography remains the
"gold-standard" in the detection of venous steno-
sis and occlusion (Fig. 2). It is also essential to
FIGURE 2 Venogram of a patient with severe stenosis of the superior vena cava.86 C. WITT et al.
establish the pattern of venous collaterals prior to
surgical placement of bypass grafts [25] (Fig. 3).
Nuclearjqow studies with 99m Technetium labeled
microspheres which are less thrombogenic than
iodinated contrast media are not routinely per-
formed as their results are less accurate [1,14].
Doppler jqow studies are useful for investigations
of peripheral venous flow (axillary, subclvian, and
jugular veins) and venous congestion in SVCS but
are of limited use in intra-thoracic veins [26,27].
MRI seems valuable in diagnosing intra-thoracic
venous obstruction with a sensitivity of 94% and
specificity of 100%, but seems less suitable for
evaluating patency after endoprothesis placement
because of stent-induced artefacts [28]. It is not
routinely performed.
Prospective studies about the role of broncho-
scopy in SVCS do not exist. However, endocopic
techniques (inspection, broncho-alveolar lavage,
forceps biopsy, needle biopsy) give valuable infor-
mations about the tumour and its histology and
helps to evaluate the risk of pulmonary complica-
tions (e.g. airway stenoses). In the first of our 13
patients who presented with SVCS and who
received a venous stent we observed tracheal com-
pression in 11 cases, right main or intermediate
bronchi compression in eight cases, and stenosis
of the left main bronchus in two cases (Table I).
Only one patient did not show any abnormal
bronchoscopical picture. In most cases broncho-
scopic procedures (biopsy, needle aspiration,
transbronchial biopsy) lead to reliable histolgical
findings. Therapeutic bronchoscopy is necessary
in certain patients with compression of the SVC
and central airways simultaneously or in the fol-
low up. In this case stenting of the airway and
SVC may be indicated (Figs. 4(a), (b)).
TREATMENT OF SVCS
Symptomatic improvement is often achieved by
oxygen, analgesia, elevation of the head of the
bed, diuretics, and corticosteroids; thereby time
can be gained to assess the situation and develop
a suitable therapeutic strategy [14].
FIGURE 3 Venous collaterals in a patient with severe SVCS.SUPERIOR VENA CAVA SYNDROME 87
Surgery, radiotherapy, and chemotherapy have
been used to treat SVCS due to malignant ob-
struction [12,29-33]. Surgical bypass of the SVC
requires thoracotomy which is best avoided in
most patients with end-stage malignant disease
[31,34], nevertheless there are several papers
describing successful palliation achieved by surgi-
cal intervention [25,35].
Radiotherapy is a well established treatment
modality for malignant SVCS but the response
TABLE Findings in the first 13 patients with SVCS treated with a venous stent. (No. =number, SCLC=small cell lung
carcinoma, NSCLC=non-small cell lung carcinoma, SVC=superior vena cava, jugular=right jugular vein, brachioceph=
brachiocephalic trunc)
No. Age/sex Tumour Airway stenoses Venous stenoses
2
3
4
5
6
7
8
9
10
ll
12
13
62/f
68/m
47/m
52/m
73/f
77/m
64/m
66/m
76/m
58/m
50/m
72/f
63/f
NSCLC trachea left SVC jugular
SCLC trachea right SVC
M. Hodgkin SVC
NSCLC trachea right SVC jugular
thyroid ca trachea left SVC
SCLC right SVC
SCLC trachea right SVC
NSCLC trachea SVC
SCLC trachea right SVC
NSCLC trachea right SVC
SCLC right SVC jugular
NSCLC trachea SVC jugular
metastasis trachea right SVC
brachioceph
brachioceph
brachioceph
brachioceph
brachioceph
brachioceph
FIGURE 4(a) In some patients vascular and airway stents have to be implanted.88 C. WITT et al.
FIGURE 4(b) Endobronchial Strecker-stent in a patient with malignant SVCS (Figs. 4(a), (b) taken from the same patient).
may be delayed for 2-3 weeks [34]. Armstrong
et al. report complete symptomatic relief in the
majority of patients with lymphoma and partial
relief in ca. 50% of patients with bronchogenic
carcinoma [4]. Irving et al. achieved relief in 90%
of the patients with malignant stenoses within
three weeks [17].
In small-cell lung cancer (SCLC) chemotherapy
is often effective. Sculier et al. report success of
chemotherapy in terms of symptomatic improve-
ment in 73% of the patients [32]. In another series
of 37 patients with SCLC complete or partial
relief was demonstrated in 84% [33].
However all tumour-specific treatment strate-
gies require some time to show effect, and some
tumours do not respond at all. Furthermore there
might be tumour recurrence after maximum irra-
diation or extensive chemotherapy and SVCS
sometimes re-occurs as an emergency which ne-
cessitates immediate action. The placement of
vascular stents seems to be an alternative in these
situations. There are numerous reports about the
use of Gianturco-, Wall-, and Palmaz-stents in
SVCS (Table II).
VENA CAVA STENTING
Various stent types have been developed for vas-
cular and extra-vascular indications (biliary stents,
oesophageal stents, tracheobronchial stents). In
the published papers about SVCS due to malig-
nant conditions Gianturco-Z-stents and Wallstents
have mostly been used [36-40]. There are several
reports about Palmaz balloon-expandable intra-
vascular stents in benign and malignant SVCS
[41-44]. Prior to stent placement thrombolysis has
been performed in some patients with SVCS or
subclavian thrombus using Streptokinase, Uro-
kinase or recombinant tissue-type plasminogen
activator (rt-PA) [6,23,45-47].
The procedure of the implantation is performed
via percutaneous femoral [5,7,8,18,23,48,49-51],
antecubital 18,51 or jugular [7,22] vein approach,SUPERIOR VENA CAVA SYNDROME 89
TABLE II Published studies, venous stent implantation in malignant superior vena cava syndrome. (w-Wallstent,
g- Gianturco-Z-stent, rec- recurrence in n cases, d days, no information)
Author Year Number of patients Immediate relief (%) rec Time until rec
Antonucci 1992 2w 100 90d
Crowe et al. 1995 11 g 100 5 14-183 d, thrombosis
Dyet et al. 1993 17w 100 2 120d, thrombosis
Edwards 1993 g 100 0 90 d
Elson et al. 1991 5 p 100 0
Ferro et al. 1995 9 g 100 2
Furui et aL 1995 16g 81 2 21 d
Gaines et al. 1994 20 g 90 3 x
Hennequin et al. 1995 14w 100 90 d, thrombosis
Irving et al. 1992 17 g 94
Kishi et al. 1993 6 g 100 60d, local metastasis
K6hler et al. 1995 w 100 130d, thrombosis
Link et al. 1995 4w 100 0 2 d
Oudkerk et al. 1992 14g+w 71 3 21 d
Putnam et al. 1988 2 g 100 0 30 d
R6sch et al. 1992 20g 100 270d, tumour ingrowth
Sawada et aL 1991 6 g 100 49 d
Solomon et al. 1991 6 g 100 2 28 d
Stock et aL 1995 14w 85 3 7/78/247 d, thrombosis
Tacke et al. 1994 8 g+w 100 0 60d, tumour compression
Watkinson et al. 1993 4w 100
Wilhelm et al. 1995 14 g+w 85 0 60d
depending on the location of the SVC-stricture
and the presence of additional occlusions in the
brachiocephalic veins. Prior to insertion of the
stent balloon dilatation can be performed [22,50],
it may be useful especially in those patients who
have short, and very tight stenoses [34]. The dila-
tation balloon also serves to delineate the extent
of the stricture [7]. The introducer catheter is then
advanced and the stent positioned across the ste-
notic area. The stent is deployed by carefully
withdrawing the sheath. If more than one stent is
used the most distal one is placed first followed
by the more proximal ones in an overlapping
arrangement [7]. Once the stent is in place a dila-
tation balloon inside the stent may be used to ac-
celerate it’s expansion and dilatate any remaining
stricture [5,7,18,23]. During the implantation pro-
cedure a bolus injection of 5000 IU heparin (iv) is
given by most authors [18,23,51,52].
In the post-interventional treatment there is no
concurrent strategy for post-stenting treatment
concerning dosages and applications of anti-
thrombotic and thrombolytic drugs. Thromboly-
tic drugs were used by Kishi et al., Furui et al.,
and Sawada et al. [5,22,50] to prevent thrombotic
re-occlusion in patients who had severe thrombo-
sis of the SVC prior to stenting or where thrombi
were seen at post interventional cavography. Oral
anticoagulation was performed during 3 or 6
months following stent implantation in patients
with pre-stenting thrombosis [18,23]. Others did
not perform oral anticoagulation at all, even if
thrombotic occlusion was present prior to stent
implantation [52]. And R6sch et al. advocate life-
long anticoagulation after stenting in all patients
with malignant SVCS [7]. Heparin was given at
therapeutic dosage for 1-5 days after the proce-
dure in most of the published series [7,8,22,23,
45,51-53]. Anti-platelet therapy was performed
by Kishi et al. using 1000mg ASS (iv) for 7 days
and 3000mg (po) for another 7 days [5]; Dyet
et al. used 300mg ASS for 3 months [23], and
Watkinson gave 75mg until patients death [8].
Most other papers do not report any anti-platelet
therapy as its effect in the venous system seems to
be uncertain [51,54].90 C. WITT et al.
FIGURE 5 Free passage of contrast media through the stented vessel (left brachiocephalic vein and SVC).
Stent insertion leads to a clinical improvement
of the venous congestion in 71% [24] to 100%,
analyzing the present papers the overall success
rate is estimated to be over 90% (Table II).
Clinical features of SVCS are reported to decrease
markedly within 48 h after the procedure [6,18,23]
(Fig. 5).
Stent insertion was not successful when the
implantation catheter could not be safely advanced
through the stenostic area [18], when strictures
were to tight for dilatation [22], when the ana-
tomic situation made stent positioning difficult
[51], and when Gianturco-stents broke after the
implantation [24]. Immediate complications of the
stenting procedure rarely appeared. Pulmonary
oedema due to sudden overload of the heart when
venous return normalizes is one of them and needs
immediate treatment [5]. Short-term complications
of SVC stent implantation are thrombosis, SVCS-
recurrence, and technical complications.
Thrombotic occlusion of the stent seems to be
a common complication and may occur in spite
of heparin treatment [52]. When anticoagulation
is discontinued, e.g. after appearance of severe
side-effects [23], thrombosis of the stented SVC
may appear [18].
Recurrence of SVCS due to tumour progres-
sion has been reported by several authors, it may
cause compression of the stented SVC [55] or
may lead to ingrowth of tumorous tissue into the
lumen of the vessel [7].
Oudkerk et al. report three cases of Gianturco-
stent fracture with a migrating fragment in one case
[24], another technical complication, Gianturco-
stent migration, is reported by Furui et al. [22].
DISCUSSION
Indications for stent implantation in malignant
SVCS have not been well defined. Care has to be
taken as the stent once implanted and completely
released cannot be removed by other means than
surgical intervention. In most series stents were
implanted in patients who already underwent
radiotherapy or chemotherapy and do not respondSUPERIOR VENA CAVA SYNDROME 91
sufficiently, in patients with recurrent SVCS, and
in patients who refused tumour-specific therapy
[22-24,56]. Kishi et al. defined rather strict indi-
cation criteria which included elevated caval
pressure (> 22mmHg), absence of vascular com-
pensation, and absence of other anticancer ther-
apy, furthermore patients cardiac function had to
be good enough to tolerate possible overload [5].
Most suitable lesions for stent implantation are
stenoses with not completely obstructed lumina
which allow free passage of the guide wire and
the introductory sheath [7].
Most authors felt that intraluminal tumour or
thrombus formation should be a contraindication
to stent placement [5,8,23]. Oudkerk et al. applied
the following contraindications: chronic complete
vessel occlusion proved by imaging, severe coagu-
lopathy, and chronic cardiac disease [24].
In the end there is little doubt that stent implan-
tation is the procedure of choice in patients with
recurrent SVCS who already underwent maxi-
mum radio- or chemotherapy.
Whether stent implantation in the SVC should
be performed as first line treatment remains
Superior, vena cava syndrome
Diagnostic procedures"
clinical examination
imaging
angiography
bronchoscopy
Early stage Late stage
(risk ofasphyxia)
Intensified
tumour-specific
therapy
no
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Venoplasty
Stent
FIGURE 6 Strategy in the treatment of the superior vena cava syndrome.92 C. WITT et al.
controversial. On the one hand some statistical
findings indicate, that in 80% of SVCS due to
small-call lung cancer chemotherapy successfully
reduces venous congestion [33,57]; in non-small
cell lung cancer response rates of radiotherapy
are reported to be between 65% and 90% within
three weeks [4,17]. On the other hand stent
implantation is an easy and relatively safe proce-
dure in the hand of an experienced specialist, it
gives immediate relief of SVCS symptoms, which
is important in patients with limited life expec-
tancy; furthermore it does not interfere at all with
any subsequent therapy [34]. For Dyet et al. [23]
stenting without prior tumour-specific therapy is
justified in patients with very severe symptoms
who would not tolerate or survive radio- or
chemotherapy.
From all reported results and published papers
we draw the conclusion, that stent implantation
and tumour-specific therapy should be combined.
The stent dilates the local venous stenosis while
tumour-specific therapy has a general effect on
the vascular and respiratory situation. In the early
stage radio- or chemotherapy should be intensi-
fied, in late stage SVCS stent implantation should
be performed as first line treatment (Fig. 6).
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